The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sravani Reddy Gantla
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.8 pts less than Nifty Microcap 250 and 4.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Sravani Reddy Gantla, a non-promoter shareholder of Oxygenta Pharmaceutical Limited, has sold 19,79,340 equity shares (5.35% of the company's equity capital) on April 16, 2025. The transaction was carried out off-market pursuant to a Memorandum of Understanding dated September 30, 2024, suggesting a pre-arranged private deal rather than an open-market sale. Following this disposal, her holding in the company dropped from 44,87,000 shares (12.13%) to 25,07,660 shares (6.78%). The filing was made under Regulation 29(2) and 29(3) of the SEBI (SAST) Regulations, 2011, which mandates disclosure for transactions exceeding 5% of shareholding.
This is a significant reduction in stake by a non-promoter shareholder, cutting her holding by more than half. While the seller is not classified as a promoter, the size of the off-market block deal could create short-term supply-side pressure if similar transactions are repeated, and the reduced float held by large shareholders may affect future liquidity in the stock.